- Report of Foreign Issuer (6-K)
October 29 2008 - 5:03AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
28 October 2008
PROTHERICS PLC
(Translation of Registrant’s Name Into
English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by
furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange
Act of 1934.
Yes
No
X
If “Yes” is marked, indicate below the
file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
.
The Registrant is furnishing a copy of its
announcements as reported to the Company Announcements Office of the London Stock
Exchange.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
PROTHERICS PLC
|
|
|
|
|
|
|
|
Date: 28 October 2008
|
|
By:
|
|
/s/ Rolf Soderstrom
|
|
|
|
|
Rolf Soderstrom
|
|
|
|
|
Finance Director
|
Protherics
PLC
Notification
of Directors' Interests
London, UK; Brentwood, TN, US: 28 October 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical company focused on
critical care and cancer, in accordance with the FSA Disclosure and Transparency
Rules, announces that, on 23 October 2008, pursuant to the
conversion of all outstanding six per cent. unsecured convertible loan notes 2010 of
Protherics, the following ordinary shares (the "Shares") were allotted to
Directors of Protherics PLC:
Director
|
Nominal Value of Loan
Notes
converted
|
Shares
allotted share
capital
|
% issued
|
Andrew
Heath
|
£24,242
|
96,968
|
0.028%
|
Stuart Wallis
|
£60,606
|
242,424
|
0.069%
|
In accordance with the Loan Note Instrument,
the Shares were allotted at a price of 25 pence per share.
Following the above allotment of Shares,
their interests in the ordinary share capital of the Company are as
follows:
|
No. Shares
|
% issued share capital
|
Andrew
Heath
|
516,778
|
0.148%
|
Stuart Wallis
|
809,113
|
0.231%
|
| Ends |
For
further information please contact:
Protherics
|
|
Nick Staples, Director of Corporate Affairs
|
+44 (0) 7919 480510
|
Julie Vickers, Company Secretary
|
+44
(0)1928 518010
|
|
|
Financial Dynamics
- press enquiries
|
|
London: Ben Atwell, Lara Mott
|
+44
(0) 20 7831 3113
|
New York: John Capodanno
|
+1 212 850 5600
|
Or visit
www.protherics.com
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Sep 2023 to Sep 2024